相关实验视频
Updated: Sep 20, 2025

10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
22.1K
[针对莫亚莫亚病的抗血小板药物治疗的证据]
1Department of Neurology and Stroke, Saitama Medical University International Medical Center.
No shinkei geka. Neurological surgery
|May 29, 2025
概括
抗血小板药物对缺血性莫亚莫亚病 (MMD) 的有效性有限,但可能有利于患有微栓塞信号的患者. 奇洛斯塔提供了多方面的好处,有可能改善MMD患者的绕道通透性和认知功能.
科学领域:
- 神经学 神经学
- 血管医学 血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 莫亚莫亚病 (MMD) 是一种罕见的脑血管疾病.
- 目前对MMD抗血小板药物的研究主要由小型观察性研究组成.
- 随机临床试验不足以建立MMD中确定的中风预防策略.
研究的目的:
- 审查关于在莫亚莫亚病中使用抗血小板药物的现有证据.
- 探索抗血小板治疗在MMD中预防中风的潜在益处和风险.
- 突出西洛斯塔在管理MMD时的特殊特性.
主要方法:
- 对回顾性观察性和前性研究的审查.
- 对MMD抗血小板药物的疗效和安全性数据的分析.
- 对微栓塞信号的跨骨多普勒超声波发现的评估.
主要成果:
- 抗血小板药物在整体上对缺血性MMD的有效性有限.
- 患有微栓塞信号的患者可能从抗血小板治疗中受益,以预防脑梗塞.
- 没有数据表明抗血小板药物会增加MMD中出血性中风风险.
- 抗血小板药物可以改善外科手术后绕道移植的通透性.
结论:
- 奇洛斯塔在MMD患者中显示出临床益处,原因是大脑血流量增加和认知能力改善.
- 需要进一步的研究,包括随机试验,以澄清抗血小板药物在预防MMD中风中的作用.
- 对于特定的MMD患者亚组,可以考虑抗血小板治疗,特别是那些患有栓塞信号或接受绕道手术的患者.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
656
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
656
Coronary Artery Disease V: Interprofessional Care
39
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
39
Peripheral Artery Disease III: Interprofessional Care
35
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
35
Anticoagulant Drugs: Low-Molecular-Weight Heparins
932
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
932
Atherosclerosis III: Management
42
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
42
Angina IV: Management
32
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
32

